p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease. A cardinal feature of the pathogenesis of IPF is excessive extracellular matrix deposition attributable to proliferation of activated fibrotic lung fibroblasts (fLfs). To assess the underlying mechanism, we analyzed the status of the tumor suppressor protein p53 in fLfs from the lungs of IPF patients or mice with bleomycin-induced established PF. We report that basal expression of p53 is markedly reduced in fLfs. Forced expression of caveolin-1 in fLfs increased basal p53 and reduced profibrogenic proteins, including collagen-1. Transduction of fLfs with adenovirus expressing p53 reduced expression of these proteins. Conversely, inhibition of baseline p53 in control lung fibroblasts from lung tissues increased profibrogenic protein expression. Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice. Furthermore, treatment of fLfs or fibrotic lung tissues with caveolin-1 scaffolding domain peptide (CSP) or its fragment, CSP7, restored p53 and reduced profibrogenic proteins. Treatment of wild-type mice with i.p. CSP or CSP7 resolved bleomycin-induced PF. These peptides failed to resolve PF in inducible conditional knockout mice lacking p53 in fLfs, indicating the induction of baseline fLf p53 as the basis of the antifibrotic effects.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cav-1 expression in pulmonary fibroblasts and alveolar epithelial cells is decreased in transgenic and rodent bleomycin models of lung injury and in the lungs of patients with IPF.
“Cav-1 expression in pulmonary fibroblasts and alveolar epithelial cells is decreased in transgenic and rodent bleomycin models of lung injury and in the lungs of patients with IPF10–12.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [11]
The Discussion and Figure 2 caption report reduced Cav1 in lung fibroblasts from patients with IPF and mice with bleomycin-induced fibrosis (page not specified in our copy). The Discussion instead describes increased Cav1 expression in injured alveolar epithelial cells; our copy does not establish the claimed decrease in those cells or in a transgenic injury model. (LLM, conf=0.89)
Experimental — accuracy not yet measuredAugmentation of endogenous Cav-1 levels and supplementation of exogenous caveolin scaffolding domain peptide have been shown to suppress lung fibrosis.
“Augmentation of endogenous Cav-1 levels and supplementation of exogenous caveolin scaffolding domain (CSD) peptide have been shown to suppress lung fibrosis7,10,11,13,14.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · see citing works
Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R. (2016) · Respiratory Research · doi:10.1186/s12931-016-0328-5 · Cited by 133 · see citing works
Flagged first, then by citations
Research works printed but not linked: 8
- Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006, 103:13180e13185
- Aoshiba K, Nagai A: Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 2003, 1:21
- Margaritopoulos GA, Vasarmidi E, Antoniou KM: Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid 2016, 11:11e22
- Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N: Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016, 5:78
- Kendall RT, Feghali-Bostwick CA: Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 2014, 5:123
- Todd NW, Luzina IG, Atamas SP: Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5:11
- Markowski DN, Helmke BM, Radtke A, Froeb J, Belge G, Bartnitzke S, Wosniok W, Czybulka-Jachertz I, Deichert U, Bullerdiek J: Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium. BMC Womens Health 2012, 12:2
- Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8
Cited by
Sorted by citations
The critical roles of caveolin-1 in lung diseases
Fan, J., Zheng, S., Wang, M., & Yuan, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1417834 · Cited by 21 · see citing works
LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF
MacKenzie, B., Mahavadi, P., Pinho Jannini-Sa, Y. A., Creyns, B., Coelho, A. L., Espindola, M., Ruppert, C., Windsor, B., Aigner, C., Hogaboam, C. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113437 · Cited by 2 · see citing works
Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study
Molyneaux, P. L., Hirani, N. A., Chia, C. C. K., Kulkarni, T., Zaman, T., Kaner, R. J., Coelho, A. L., Jannini-Sa, Y. A. P., Windsor, B., Kruger, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75291-3 · Cited by 1 · see citing works
“Augmentation of endogenous Cav-1 levels and supplementation of exogenous caveolin scaffolding domain (CSD) peptide have been shown to suppress lung fi brosis 7,10,11,13,14 .”
- Authors
- Nagaraja, M. R., Tiwari, N., Shetty, S. K., Marudamuthu, A. S., Fan, L., Ostrom, R. S., Fu, J., Gopu, V., Radhakrishnan, V., Idell, S., & Shetty, S.
- Affiliations
- The University of Texas Health Science Center at Tyler (US)
- Chapman University (US)
- University of Kentucky (US)
- Corresponding author
- Shetty, Sreerama
- ORCID
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 188
- Issue
- 10
- Pages
- 2207-2222
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC6168957
- OpenAlex
- W2892840122
- Cited by
- 37
- References
- 2
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 5 · 2019: 2
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Chapman University Digital Commons (Chapman University) (submittedVersion)
- Funders
- Flight Attendant Medical Research Institute (150063)
- National Institutes of Health (R01HL133067-01, R21ES025815)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- p53, idiopathic pulmonary fibrosis, lung fibroblasts, caveolin-1, bleomycin-induced lung fibrosis, extracellular matrix deposition, collagen-1, antifibrotic therapy
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Bleomycin, Fibroblasts, Humans, Mice, Inbred C57BL, Peptide Fragments, Transduction, Genetic, Tumor Suppressor Protein p53, Caveolin 1, Idiopathic Pulmonary Fibrosis, Airway Remodeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review